Applied DNA Sciences (APDN) received a seventh follow-on order valued at more than $600,000 for a multi-gram quantity of LineaDNA. The follow-on order was placed by a global manufacturer of in vitro diagnostics under a long-standing supply agreement for the bulk manufacture of LineaDNA used as a functional component of a cancer diagnostic test. Deliveries are scheduled across four quarterly shipments beginning in the second quarter of fiscal 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APDN:
- Applied DNA Sciences Regains Nasdaq Compliance
- Applied DNA regains compliance with Nasdaq continued listing requirements
- Applied DNA Sciences Announces Strategic Restructuring
- Applied DNA Sciences announces restructuring, 27% workforce reduction
- Applied DNA Sciences CEO James Hayward Announces Retirement